 Imprimir -
 Enviar a un amigo - Cerrar Ventana
Jueves 17 de Diciembre de 2009
The efficacy of calcitriol therapy in the management of bone loss and fractures: A qualitative review
Primary osteoporosis is usually a result of reduced bone mineral density as a consequence of natural aging.
Secondary osteoporosis is usually a result of a disease, such as cystic fibrosis, or medical treatment, such as corticosteroids or cancer treatment. Calcitriol, alone or in combination with other agents, should be considered for the therapy of osteoporosis.
Methods - systematic qualitative review of clinical trials that assessed calcitriol for the treatment of osteoporosis and bone loss
- In these clinical trials, calcitriol used as monotherapy and in combination with other therapeutic bone agents
Results - Studies using calcitriol monotherapy, although not conclusive, found that calcitriol slowed rate of bone loss in variety of populations
- Calcitriol in combination with other therapeutic bone agents shown to have additional bone-preserving effects when compared to use of therapeutic bone agents alone
- Common side-effect of calcitriol therapy was hypercalcemia and hypercalciuria, but degree of hypercalcemia was mild
- Recent research found that intermittent dosing can reduce hypercalcemia rates
mdlink.com
Por para MG-MedicinaGeriátrica |
